TY - JOUR
T1 - Genetic screens identify a context-specific pi3k/p27kip1 node driving extrahepatic biliary cancer
AU - Falcomatà, Chiara
AU - Bärthel, Stefanie
AU - Ulrich, Angelika
AU - Diersch, Sandra
AU - Veltkamp, Christian
AU - Rad, Lena
AU - Boniolo, Fabio
AU - Solar, Myriam
AU - Steiger, Katja
AU - Seidler, Barbara
AU - Zukowska, Magdalena
AU - Madej, Joanna
AU - Wang, Mingsong
AU - Öllinger, Rupert
AU - Maresch, Roman
AU - Barenboim, Maxim
AU - Eser, Stefan
AU - Tschurtschenthaler, Markus
AU - Mehrabi, Arianeb
AU - Roessler, Stephanie
AU - Goeppert, Benjamin
AU - Kind, Alexander
AU - Schnieke, Angelika
AU - Robles, Maria S.
AU - Bradley, Allan
AU - Schmid, Roland M.
AU - Schmidt-Supprian, Marc
AU - Reichert, Maximilian
AU - Weichert, Wilko
AU - Sansom, Owen J.
AU - Morton, Jennifer P.
AU - Rad, Roland
AU - Schneider, Günter
AU - Saur, Dieter
N1 - Publisher Copyright:
© 2021, American Association for Cancer Research Inc.. All rights reserved.
PY - 2021/12
Y1 - 2021/12
N2 - Biliary tract cancer ranks among the most lethal human malignancies, representing an unmet clinical need. Its abysmal prognosis is tied to an increasing incidence and a fundamental lack of mechanistic knowledge regarding the molecular basis of the disease. Here, we show that the Pdx1-positive extrahepatic biliary epithelium is highly susceptible toward transformation by activated PIK3CAH1047R but refractory to oncogenic KrasG12D. Using genome-wide transposon screens and genetic loss-of-function experiments, we discover context-dependent genetic interactions that drive extrahepatic cholangiocarcinoma (ECC) and show that PI3K signaling output strength and repression of the tumor suppressor p27Kip1 are critical context-specific determinants of tumor formation. This contrasts with the pancreas, where oncogenic Kras in concert with p53 loss is a key cancer driver. Notably, inactivation of p27Kip1 permits KrasG12D-driven ECC development. These studies provide a mechanistic link between PI3K signaling, tissue-specific tumor suppressor barriers, and ECC pathogenesis, and present a novel genetic model of autochthonous ECC and genes driving this highly lethal tumor subtype. SIGNIFICANCE: We used the first genetically engineered mouse model for extrahepatic bile duct carcinoma to identify cancer genes by genome-wide transposon-based mutagenesis screening. Thereby, we show that PI3K signaling output strength and p27Kip1 function are critical determinants for contextspecific ECC formation.
AB - Biliary tract cancer ranks among the most lethal human malignancies, representing an unmet clinical need. Its abysmal prognosis is tied to an increasing incidence and a fundamental lack of mechanistic knowledge regarding the molecular basis of the disease. Here, we show that the Pdx1-positive extrahepatic biliary epithelium is highly susceptible toward transformation by activated PIK3CAH1047R but refractory to oncogenic KrasG12D. Using genome-wide transposon screens and genetic loss-of-function experiments, we discover context-dependent genetic interactions that drive extrahepatic cholangiocarcinoma (ECC) and show that PI3K signaling output strength and repression of the tumor suppressor p27Kip1 are critical context-specific determinants of tumor formation. This contrasts with the pancreas, where oncogenic Kras in concert with p53 loss is a key cancer driver. Notably, inactivation of p27Kip1 permits KrasG12D-driven ECC development. These studies provide a mechanistic link between PI3K signaling, tissue-specific tumor suppressor barriers, and ECC pathogenesis, and present a novel genetic model of autochthonous ECC and genes driving this highly lethal tumor subtype. SIGNIFICANCE: We used the first genetically engineered mouse model for extrahepatic bile duct carcinoma to identify cancer genes by genome-wide transposon-based mutagenesis screening. Thereby, we show that PI3K signaling output strength and p27Kip1 function are critical determinants for contextspecific ECC formation.
UR - http://www.scopus.com/inward/record.url?scp=85121982407&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-21-0209
DO - 10.1158/2159-8290.CD-21-0209
M3 - Article
C2 - 34282029
AN - SCOPUS:85121982407
SN - 2159-8274
VL - 11
SP - 3158
EP - 3177
JO - Cancer Discovery
JF - Cancer Discovery
IS - 12
ER -